CJC-1295 + Ipamorelin refers to a combination of two GH-axis peptides: a growth hormone–releasing hormone (GHRH) analog (CJC-1295) and a growth hormone secretagogue (ipamorelin). The combination is often positioned conceptually as targeting both upstream GHRH signaling and downstream secretagogue pathways.

In practice, combination products or protocols of this type are largely found in experimental or wellness contexts rather than in mainstream endocrine guidelines.

At a high level, the combination aims to:

• Use CJC-1295 to act at GHRH receptors in the pituitary, promoting physiologic GH release and influencing IGF-1 over time
• Use ipamorelin to stimulate the growth hormone secretagogue receptor (GHSR), further supporting pulsatile GH output

How these mechanisms interact in specific individuals—and whether combination use confers meaningful advantages or risks compared with single agents—remains an area of ongoing discussion rather than settled evidence.

Combination CJC-1295 + Ipamorelin products are not generally part of labeled, first-line therapies for GH deficiency. They more commonly appear in wellness or performance narratives that extend beyond the scope of established guidelines.

For individuals with suspected GH-axis disorders, clinicians typically rely on structured diagnostic approaches and single-agent therapies with more robust regulatory and evidentiary backing. Any combination strategy should be evaluated against these standards and local regulations.

Both CJC-1295 and Ipamorelin are prohibited by WADA under category S2.

Notable athlete sanctions involving this specific combination include:

• Joey Coste (CrossFit): Received a 4-year sanction in 2022 specifically for the use of CJC-1295 and Ipamorelin.

Reported or theoretical risks include injection-site reactions, flushing, headache, changes in sleep or appetite, and broader GH/IGF-1–related concerns such as effects on glucose metabolism, fluid balance, and tissue growth over time.

Because evidence on combined use is more limited than for single agents, risk– benefit assessment requires particular caution and is best handled by clinicians familiar with GH physiology and current practice standards.

CJC-1295 (without DAC) and Ipamorelin are synergistic, often mixed 1:1.

This information summarizes commonly discussed research practices.

In catalogs, CJC-1295 + Ipamorelin may appear as a single vial or preblended product that combines the two peptides at fixed ratios. It may also be discussed conceptually as a protocol that uses separate vials together.

Structural listings on this site document vial codes and specifications but do not endorse specific mixing strategies, sequences, or target populations.

Formal research on simultaneous use of GHRH analogs and GH secretagogues is more limited than that on each class alone. Some work has explored GH/IGF-1 responses and tolerability when pathways are stimulated in parallel, but long- term clinical outcome data are sparse.

As a result, combination protocols are best viewed as conceptual extensions of single-agent strategies rather than as well-validated therapies. High-level overviews like this should not be used to justify specific regimens.

Future FAQs may address why some practitioners discuss multi-agent GH-axis approaches, how clinicians weigh added complexity and uncertainty, and how combination concepts compare with simpler single-agent options. Responses will remain educational and non-prescriptive.